ConductScience.org, home

Paper42885307PubMed

Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway.

Cui S and 7 others. Int J Mol Med, 2026.

Cite this record

ConductScience Library. Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway. Papers, record 42885307. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42885307

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Resveratrol alleviates osteoarthritis progression by inhibiting NLRP3 inflammasome response via the AMPK/PPARγ signaling pathway.
Journal
Int J Mol Med
Year
2026
Publication types
Journal Article
Revised in PubMed
2026-10-29

Source PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cui SShanshan
2Luo ZZifan
3Qin WWen
4Chen BBo
5Zhang QQiaoxia
6Ma JJianbing
7Ma JJie
8Zhang RRui

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
NLR Family, Pyrin Domain-Containing 3 ProteinMajor topic
ResveratrolMajor topic
OsteoarthritisMajor topic
PPAR gammaMajor topic
InflammasomesMajor topic
AMP-Activated Protein KinasesMajor topic
Signal TransductionMajor topic
Animals
Mice
Humans
Male
Disease Progression

Source PubMed

Download CSV of topics

References66

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140896702Resveratrol as a naturally occurring inflammasome modulator: Implications for health and disease.Iran J Basic Med Sci2025https://conductscience.org/library/papers/40896702PubMed
238229660The IRF1/GBP5 axis promotes osteoarthritis progression by activating chondrocyte pyroptosis.J Orthop Translat2024https://conductscience.org/library/papers/38229660PubMed
333936363Effect of resveratrol on abnormal bone remodeling and angiogenesis of subchondral bone in osteoarthritis.Int J Clin Exp Pathol2021https://conductscience.org/library/papers/33936363PubMed
439376171The role and current research status of resveratrol in the treatment of osteoarthritis and its mechanisms: a narrative review.Drug Metab Rev2024https://conductscience.org/library/papers/39376171PubMed
534917160Identification of the Resveratrol Potential Targets in the Treatment of Osteoarthritis.Evid Based Complement Alternat Med2021https://conductscience.org/library/papers/34917160PubMed
640502812Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects.MedComm (2020)2025https://conductscience.org/library/papers/40502812PubMed
716978198Synovitis score: discrimination between chronic low-grade and high-grade synovitis.Histopathology2006https://conductscience.org/library/papers/16978198PubMed
833805920Establishing SW1353 Chondrocytes as a Cellular Model of Chondrolysis.Life (Basel)2021https://conductscience.org/library/papers/33805920PubMed
932156705Metformin limits osteoarthritis development and progression through activation of AMPK signalling.Ann Rheum Dis2020https://conductscience.org/library/papers/32156705PubMed
1038890638Cartilage progenitor cells derived extracellular vesicles-based cell-free strategy for osteoarthritis treatment by efficient inflammation inhibition and extracellular matrix homeostasis restoration.J Nanobiotechnology2024https://conductscience.org/library/papers/38890638PubMed
1137020714PPAR-γ Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1α/Δψ m Pathways by Inhibiting Pyroptosis.PPAR Res2023https://conductscience.org/library/papers/37020714PubMed
1225940958Mitochondrial biogenesis is impaired in osteoarthritis chondrocytes but reversible via peroxisome proliferator-activated receptor γ coactivator 1α.Arthritis Rheumatol2015https://conductscience.org/library/papers/25940958PubMed
1311263774Peroxisome proliferator--activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes.Arthritis Rheum2001https://conductscience.org/library/papers/11263774PubMed
1437341015Buspirone attenuated methotrexate-induced hippocampal toxicity in rats by regulating Nrf2/HO-1, PPAR-γ, NF-κB/nNOS, and ROS/NLRP3/caspase-1 signaling pathways.J Biochem Mol Toxicol2023https://conductscience.org/library/papers/37341015PubMed
1522258606Inflammasomes in health and disease.Nature2012https://conductscience.org/library/papers/22258606PubMed
1641793791KLK8 promotes cartilage degradation and pyroptosis in osteoarthritis by activating the NF-κB and NLRP3 inflammasome pathways.Tissue Cell2026https://conductscience.org/library/papers/41793791PubMed
1728989978The therapeutic potential of resveratrol: a review of clinical trials.NPJ Precis Oncol2017https://conductscience.org/library/papers/28989978PubMed
1828627596Regulation of type II collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1β is mediated by curcumin via inhibition of NF-κB signaling in rat chondrocytes.Mol Med Rep2017https://conductscience.org/library/papers/28627596PubMed
1923333322Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.Pharmacol Ther2013https://conductscience.org/library/papers/23333322PubMed
2030195731Smiglaside A ameliorates LPS-induced acute lung injury by modulating macrophage polarization via AMPK-PPARγ pathway.Biochem Pharmacol2018https://conductscience.org/library/papers/30195731PubMed

See all 66 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42885307

GET https://conductscience.org/api/papers/v1/42885307/references?page=2